Low-dose Versus Standard Dose Alteplase in Acute Ischemic Stroke , 4 Monthes Prospective Study
Status:
Completed
Trial end date:
2019-02-14
Target enrollment:
Participant gender:
Summary
Cohort A Randomized Control trial of Ateplase 0.6, 0.75 and 0.9 mg/kg in 78 patients Cohort B
single arm 0.9 mg/kg Ateplase in 330 patients Combined Cohort A and B evaluate different of
death, intra-cerebral hemorrhage, numberof patient with mRS 0-1 at discharge and 3 months
follow up, and other important stroke outcomes